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Abstract
Background: Household transmission of influenza can affect the daily lives of patients and their families and be a trigger for
community transmission, thus it is necessary to take precautions to prevent household transmission. We aimed to
determine the risks of household transmission of pandemic (H1N1) 2009 influenza virus from an index patient who visited a
primary clinic and was treated with antiviral drugs.
Methods: We followed up all the patients who were diagnosed with influenza A by rapid diagnostic test with a
questionnaire or interview from July 2009 to April 2010. Secondary cases were defined as patients visiting the clinic or other
clinics and being positive for influenza A by rapid diagnostic test within 7 days of onset of an index patient. Logistic
regression analysis was used to explore the association between household transmission and the studied variables.
Results: We recruited 591 index patients and 1629 household contacts. The crude secondary attack rate was 7.3% [95%
confidence interval (CI): 6.1–8.7]. Age of index patients (0–6 years old: odds ratio 2.56; 95% CI: 1.31–4.01; 7–12 years old:
2.44, 1.31–3.72; 30–39 years old 3.88; 2.09–5.21; 40 years old or more 2.76; 1.17–4.53) and number of household members
with five or more (3.09, 2.11–4.07), medication started $48 hours from the onset of fever (2.38, 1.17–3.87) were significantly
associated with household transmission.
Conclusions: Household transmission was associated with index patients aged #12 years old and adults $30 years with
children, with more than five persons in the household, and medication initiated $48 hours from the onset of fever among
the population, in which, antiviral treatment was given to all patients. We need to warn patients at high risk of household
transmission to take additional precautions.
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Introduction
The household of an influenza patient could be at high risk of
infection [1–3]. The secondary attack rate (SAR) of pandemic
(H1N1) 2009 in 2009 was 10–45% [1–7]. Household transmission
could result in the burden of taking care of patients at home for
several days and affect their daily lives, and an additional financial
burden because parents cannot go to work [8,9]. Household
transmission could also be a trigger of community transmission.
Understanding risk factors of household transmission is critical for
minimizing the impact of influenza. A variety of risk factors have
been identified, such as age of the index patient and number of
household members [2–4,6,10,11]. Household transmission can be
reduced if additional precautions, such as maintaining distance
between patients and healthy household members, are imple-
mented in household.
In Japan, the case fatality rate of influenza was relatively low
comparing with other countries [12,13]. One of the reasons could
be the accessibility of antiviral medications for patients at primary
clinics because of universal health coverage [13,14]. However,
treatment with neuraminidase inhibitors zanamivir or oseltamivir,
for patients who are infected with influenza virus is not conclusive
for prevention of household transmission of influenza [15,16],
even though the mechanisms of neuraminidase inhibitors interfere
with the release of progeny influenza virus from infected cells, and
are effective for treatment and resolving viral shedding [16,17].
There have been studies on household transmission of influenza in
cases when not all the patients have taken antiviral drugs,
however, there has been few studies on risk factors of household
transmission when all patients have been prescribed antiviral
medication. The aim of the this observational cohort study in
Japan was to determine risks of household transmission of
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31519pandemic (H1N1) 2009 virus from index patients who visited a
primary clinic and took an antiviral drug during the first wave of
influenza in 2009.
Materials and Methods
Data collection
We implemented this prospective cohort study at a primary
clinic in Kawasaki city, Kanagawa, Japan (population 1,410,000)
from 22 July 2009 to 19 April 2010 when the first epidemic wave
of influenza occurred in Japan after the identification of pandemic
(H1N1) 2009 influenza virus in Mexico in April 2009 [18].
We obtained clinical information on prescribed antiviral
medicine from the medical chart and disseminated a self-
administered questionnaire to all the index patients or their
families. A questionnaire comprised the number in the household
(including the index patient), time from onset of fever of the index
patient to initiating drug treatment and to onset of symptoms of
household members who had secondary transmission of influenza
A, and the existence of household members who were diagnosed
with influenza A within 7 days of onset of the index patient. A
questionnaire was returned to the clinic by FAX, or by mail, or
submitting at the counter of the clinic. In the case of a
questionnaire not being returned, we contacted the patient or
patient family to ask them to send it back or to be interviewed.
Definition of index patient
We defined an index patient as the first person that had
influenza-like symptoms, which were fever ($37.5uC) plus cough
and/or sore throat in his/her household, and were identified with
influenza A virus by a rapid diagnostic test. In patients who had
influenza-like illness but who were negative by a rapid diagnostic
test, and the time interval from onset of symptoms to visiting the
clinic was ,24 hours, we performed a rapid diagnostic test on the
next day, and prescribed antiviral medication based on diagnosis
by a clinician. Households that consisted of at least two persons
were eligible for study participation.
Definition of household transmission
We defined household transmission as a household member
who visited the same clinic or other clinics, who was then
diagnosed with influenza A by rapid diagnostic test within 7 days
after the index patient started to develop influenza like symptoms.
Drug administration
All index patients received treatment with oseltamivir or
zanamivir twice daily for 5 days, with the dose based on their
body weight, as soon as patients were diagnosed with influenza.
The choice of antiviral drug was not randomized and took into
consideration patients’ preferences for either oral or inhalational
administration. In Japan, there are concerns that oseltamivir
administration in teenagers can cause psychological and neuro-
psychiatric side effects [19]. Thus, in this study, oseltamivir for
teenagers were prescribed only when the index patient seemed not
to be able to inhale zanamivir. We did not prescribe antiviral
drugs for prophylaxis for healthy household individuals.
Statistical analysis
SARs were calculated according to the number of persons who
were determined as ‘‘household transmission’’ divided by the total
number of enrolled household members excluding the total
number of index patients. Pearson’s x
2 test was used to compare
categorical variables and the t test for continuous variables.
Logistic regression analysis with a generalized estimating equation
was used to determine the association between household
transmission and the studied variables. We first examined the
variables by univariate analysis, and then by multivariate analysis
without factors not significant at P=0.10 in univariate analysis. All
analyses were performed using IBM SPSS Statistics 19. Since the
incidence of household transmission was not rare, we corrected
odds ratio with Zhang’s formula [20].
Ethics statement
The Human Research Committee at the Kitasato University
School of Medicine approved this study. We obtained a written
consent with submitting a voluntary questionnaire.
Results
We recruited 591 index patients and 1629 household contacts.
Eighty-six patients did not return the questionnaire or respond to
the interview and were excluded from the study. Table 1 shows the
characteristics of index patients according to age group. The peak
age band of index patients was 7–12 years old. Overall, 119
secondary cases occurred among 1629 household contacts, giving
a SAR of 7.3% (95% CI: 6.1–8.7). Ninety-seven percent of index
patients started antiviral medication within 48 hours of the onset
of fever.
Figure 1 shows the distribution of days from onset of fever in the
index patients to onset of influenza-like illness in the secondary
cases. Half of the secondary cases developed fever within 48 hours
after the index patient had fever. However, there were a few cases
of household transmission at 96 hours after development of
symptoms in the index patients.
Table 2 shows the association of household transmission with
the study variables. The rate of household transmission by age of
the index patient peaked among patients aged 30–39 years old
with a SAR of 19.7 (11.8–31.0). For patients aged $30 years, only
two index patients did not have any children, while the others with
secondary transmission were mothers (22.9% of index mother
patients) and fathers (36.8% of index father patients). The SAR
were higher in households with more than five people (11.1 (7.7–
14.5)) among patients who took oseltamivir (9.7 (7.7–11.8)); and
when the time from onset of fever to initiating medication was
48 hours or more (18.3 (8.5–28.1)).
Table 3 shows logistic regression analysis between household
transmission and the studied variables. Age of index patients [0–6
years old, odds ratio (OR): 2.56, 95% CI: 1.31–4.01; 7–12 years
old, 2.44, 1.31–3.72; 30–39 years old 3.88, 2.09–5.21; $40 years
old, 2.76, 1.17–4.53] and number of household members (five or
more 3.09, 2.11–4.07) were significantly associated with household
transmission. Differences in antiviral medication were significantly
associated with household transmission in univariate analysis,
however, it was not significantly associated in multivariate analysis.
Initiation of antiviral medicine after 48 hours (2.38, 1.17–3.87)
was significantly associated with household transmission.
Discussion
The present prospective cohort study elucidated the risk factors
that were associated with household transmission among the
patients infected with influenza A, with antiviral drug treatment
(oseltamivir or zanamivir) during the first wave of pandemic
influenza virus (H1N1) 2009 at a primary clinic in Japan. We
found that age #12 and $30 years old with children, households
with more than five members, and initiation of antiviral therapy
$48 hours were associated with household transmission. Differ-
ences in antiviral drug treatment were not significantly associated
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even though the SAR of zanamivir was significantly lower than
that of oseltamivir.
The most identified type of influenza A virus from 22 July 2009
to 19 April 2010 according to national influenza surveillance in
Japan was pandemic (H1N1) 2009 [21]. In the present study, we
identified influenza A with a rapid antigen diagnostic test, and
polymerase chain reaction testing was conducted by the Kawasaki
City Institute for Public Health to confirm the pandemic (H1N1)
2009 virus for all 224 cases that were positive for influenza A until
21 October 2009. All the 242 cases were confirmed to be infected
with pandemic (H1N1) 2009. We assumed that most patients were
infected with pandemic (H1N1) 2009 virus in the study period.
Vaccination against pandemic (H1N1) 2009 virus in Japan had
been provided according to the list of prioritized groups from
November 2009 and became available for everyone from January
2010. Thus, we did not take the effect of vaccination into account
in this study.
The age group that was most frequently infected by pandemic
(H1N1) 2009 virus in Japan in 2009 was 10–19 years old, and 65%
of this age group were infected in the first wave of 2009, according
to a national survey of antibody titer [22]. In our study, the rate of
secondary transmission among the index patients who were 13–19
years old (3.3%) and 20–29 years old (5.1%) was lower compared
with other age groups. It is possible that those aged 13–29 years
maintained a distance from other household contacts to avoid
Figure 1. Distribution of days (serial interval) from onset of illness in the index patient to onset of influenza-like illness in the
secondary case, Kawasaki, Japan 2009 (n=97).
doi:10.1371/journal.pone.0031519.g001
Table 1. Characteristics of the index patients according to age group.
Total 0–6 Yr 7–12 Yr 13–19 Yr 20–29 Yr 30–39 Yr $40 Yr
Category (n=591) (n=158) (n=232) (n=111) (n=32) (n=26) (n=32)
Number of household contacts (including the index patient)
Two to three 229 (39) 59 (37) 104 (45) 31 (28) 8 (25) 14 (54) 13 (41)
Four 283 (48) 82 (52) 101 (44) 59 (53) 16 (50) 9 (35) 16 (50)
Five or more 79 (13) 17 (11) 27 (11) 21 (19) 8 (25) 3 (11) 3 (9)
Number of secondary cases in household
None 494 (84) 127 (80) 193 (83) 103 (93) 28 (88) 17 (65) 26 (81)
One 80 (14) 25 (16) 36 (16) 5 (5) 3 (9) 6 (23) 5 (16)
Two 12 (2) 6 (4) 1 (0) 1 (1) 1 (3) 2 (8) 1 (3)
Three 5 (1) 0 (0) 2 (1) 2 (2) 0 (0) 1 (4) 0 (0)
Treatment
Zanamivir 296 (50) 22 (14) 149 (64) 103 (93) 7 (22) 6 (23) 9 (28)
Oseltamivir 295 (50) 136 (86) 83 (35) 8 (7) 25 (78) 20 (77) 23 (72)
Time interval from onset of fever to take the first medication
Less than 48 hours 571 (96) 155 (98) 224 (97) 105 (95) 31 (97) 24 (92) 32 (100)
48 hours or more 20 (4) 3 (2) 8 (3) 6 (5) 1 (3) 2 (8) 0 (0)
CI; Confidence interval.
doi:10.1371/journal.pone.0031519.t001
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there is a high risk of household transmission when index patients
are preschool age [4,6,23–25], whereas we found that people aged
$30 years also had a high risk of household transmission, as well
as those who were #12 years old. All of those who were $30 years
of age in the present study were parents, and it is possible that they
might not avoid close contact when taking care of their children at
home. Children aged #12 years old tend to have longer periods of
shedding influenza virus and do not comply with hygiene and
precautions against infection [4,25–27].
Table 2. Association between household transmission and the studied variables.
Category
With household
transmission n=97 Total n=591 SAR (95% CI), % P
Age of index patients, years
0–6 31 158 8.8 (6.5–11.9) ,0.01
7–12 39 232 7.2 (5.5–9.6)
13–19 8 111 3.3 (1.8–5.9)
20–29 4 32 5.1 (1.9–11.6)
30–39 9 26 19.7 (11.8–31.0)
$40 6 32 8.5 (3.9–16.9)
Number of household contacts (including the index patient)
Two to three 26 229 6.3 (4.0–8.5) ,0.01
Four 45 283 6.5 (4.8–8.2)
Five or more 26 79 11.1 (7.7–14.5)
Treatment
Zanamivir 38 294 5.0 (3.5–6.6) ,0.01
Oseltamivir 59 293 9.7 (7.7–11.8)
Time interval from onset of fever to taking the first medication
Less than 48 hours 90 571 6.9 (5.7–8.2) ,0.01
48 hours or more 7 20 18.3 (8.5–28.1)
CI: confidence interval.
SAR: secondary attack rate.
doi:10.1371/journal.pone.0031519.t002
Table 3. Risk factors for household transmission of pandemic H1N1 (2009) from index patients treated with antiviral medicine.
Univariate analysis Multivariate analysis
Category OR (95%CI) OR (95%CI)
Age of index patients, years
0–6 2.32 (1.30–3.56) 2.56 (1.31–4.01)
7–12 2.06 (1.14–3.24) 2.44 (1.31–3.72)
13–19 1 1
20–29 1.62 (0.56–3.43) 1.44 (0.44–3.35)
30–39 3.49 (1.90–4.86) 3.88 (2.09–5.21)
$40 2.24 (0.96–3.94) 2.76 (1.17–4.53)
Number of household contacts (including the index patient)
Two to three 1 1
Four 1.37 (0.90–2.00) 1.51 (0.98–2.19)
Five or more 2.62 (1.75–3.56) 3.09 (2.11–4.07)
Treatment
Zanamivir 1 1
Oseltamivir 1.55 (1.09–2.11) 1.20 (0.75–1.83)
Time interval from onset of fever to taking the first medication
Less than 48 hours 1 1
48 hours or more 2.19 (1.09–3.60) 2.38 (1.17–3.87)
doi:10.1371/journal.pone.0031519.t003
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members or more was a risk factor even though some studies
indicated household size has not been determined as a risk factor
for domestic transmission [4,22]. Family size and the number of
children are recognized as risk factors for household transmission
in previous studies [5,28,29]. However, contact between patients
and healthy persons in the household could differ based on
cultural and familial factors and the size of the house [24].
The effectiveness of antiviral medication (zanamivir or oseltami-
vir) to reduce household transmission in index patients is
controversial [16,30–32]. Antiviral medication for patients could
have some effect on preventing household transmission. Nishiura et
al. have shown that zanamivir reduces the risk of household
transmission among patients who are infected with pandemic
(H1N1) 2009 virus in Japan [33]. In our study, there was a
significant differenceof the SARbetween zanamivirand oseltamivir
for the index patients with regard to household transmission;
however the logistic regression analysis did not identify a significant
difference. This was possibly due to the limited number of
participants, which influenced our ability to detect the difference.
Based on the age stratified analysis, the population treated with
zanamivir had a lower risk of secondary transmission even though
there was a bias for prescribing zanamivir for 10–19 year-old
patients who had lower secondary attack rate resulting in risk of
indicating a spurious preventing effect. Further studies are needed
to elucidate the effectiveness of each antiviral medication for
prevention of household transmission.
Early antiviral medication might minimize the risk of household
transmission. Ng et al. have shown that treatment by oseltamivir
within 24 hours reduced household transmission of influenza
significantly compared with no antiviral treatment [16]. Pebody
et al. have shown a significant reduction of influenza with antiviral
treatment of the index patient within 48 hours [32]. Our study
also showed that antiviral treatment after 48 hours resulted in a
higher risk of household transmission, when compared with a
group with early antiviral treatment, although there were a limited
number of patients who had antiviral treatment after 48 hours.
However, the interval before secondary transmission indicates how
quickly an epidemic can evolve in a household [2,6]. Half of
patients with household transmission of influenza have symptoms
within 48 hours of symptom onset in index patients. Transmission
occurs very early in the development of symptoms in the index
patient, which might not be preventable by early antiviral
treatment because of the time required to obtain antiviral
medicine at a clinic. In addition, shedding of seasonal influenza
virus has been identified before one day of peak of influenza like
symptoms [34]. Further studies are needed to elucidate how much
early treatment could be effective for preventing household
transmission, and how early people should take antiviral
medication for preventing household transmission. Physical
intervention for preventing household transmission is also needed,
such as hand washing, especially in the early phase of illness.
However, measures such as maintaining distance from or isolation
of the patient is difficult if small children are infected [35,36].
Some of the secondary household transmission cases in this
study might have been caused by infections from outside of their
household, as many people were infected with pandemic (H1N1)
2009 in their communities during the study period. However, the
partial correlation coefficients between the weekly accumulated
secondary transmission cases, and the weekly-accumulated
number of influenza patients who did not have any family
members diagnosed with influenza within seven days, which could
reflect the community transmission in this data setting was
20.00019. This was adjusted for the weekly-accumulated numbers
of first patients in their households. Thus, the number of patients
infected with pandemic (H1N1) 2009 outside of their household
was likely to be minimal, although further studies are still needed
to elucidate the impact of these cases on secondary household
transmission of influenza with mathematical modeling.
There were a few limitations in our study. First, the
generalizability of our results was limited to the population treated
with antiviral medicine. Second, we neither followed-up patients
by home visits nor disregarded the possible significance of
subclinical or asymptomatic infection. Third, biases could have
further arisen from the potential that all index patients recruited
had to be sick enough to initially seek medical attention, thus
selecting for ‘‘sicker’’ patients who may have had a higher degree
of ‘‘infectiousness’’.
Household transmission was associated with index patients aged
,12 years old and adults $30 years with children; more than five
persons in the household; initiation of treatment at $48 hours
from onset of fever within the population treated with antiviral
medicine. We need to warn patients at high risk of household
transmission to take additional precautions.
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